Moreover, the 36-month beta value for INM is 0.79. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for INM is 3.29M and currently, short sellers hold a 1.14% of that float. On September 11, 2024, INM’s average trading volume was 7.09M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
INM) stock’s latest price update
The stock of InMed Pharmaceuticals Inc (NASDAQ: INM) has increased by 3.67 when compared to last closing price of 0.26. Despite this, the company has experienced a -13.78% fall in its stock price over the last five trading sessions. newsfilecorp.com reported 2024-08-21 that InMed’s intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use Vancouver, British Columbia–(Newsfile Corp. – August 21, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three U.S. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. The method of use patent, entitled “Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders” relates to INM-755 drug candidate which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa.
INM’s Market Performance
InMed Pharmaceuticals Inc (INM) has experienced a -13.78% fall in stock performance for the past week, with a 93.50% rise in the past month, and a 9.63% rise in the past quarter. The volatility ratio for the week is 16.52%, and the volatility levels for the past 30 days are at 19.07% for INM. The simple moving average for the last 20 days is -6.46% for INM stock, with a simple moving average of -14.38% for the last 200 days.
INM Trading at 6.16% from the 50-Day Moving Average
After a stumble in the market that brought INM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.98% of loss for the given period.
Volatility was left at 19.07%, however, over the last 30 days, the volatility rate increased by 16.52%, as shares surge +83.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.03% upper at present.
During the last 5 trading sessions, INM fell by -13.78%, which changed the moving average for the period of 200-days by -28.73% in comparison to the 20-day moving average, which settled at $0.2958. In addition, InMed Pharmaceuticals Inc saw -34.88% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INM starting from MANCINI ALEXANDRA DIANE JANET, who sale 240 shares at the price of $0.18 back on Jul 31 ’24. After this action, MANCINI ALEXANDRA DIANE JANET now owns 0 shares of InMed Pharmaceuticals Inc, valued at $42 using the latest closing price.
HULL ANDREW, the Director of InMed Pharmaceuticals Inc, purchase 37,500 shares at $0.39 during a trade that took place back on Feb 21 ’24, which means that HULL ANDREW is holding 38,258 shares at $14,625 based on the most recent closing price.
Stock Fundamentals for INM
Current profitability levels for the company are sitting at:
- -1531.59 for the present operating margin
- 0.32 for the gross margin
The net margin for InMed Pharmaceuticals Inc stands at -0.95. The total capital return value is set at -830.33. Equity return is now at value -51.73, with -43.26 for asset returns.
Based on InMed Pharmaceuticals Inc (INM), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -6.21. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -96.15.
Currently, EBITDA for the company is -7.73 million with net debt to EBITDA at 1.06. When we switch over and look at the enterprise to sales, we see a ratio of -0.64. The receivables turnover for the company is 30.88for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.
Conclusion
To wrap up, the performance of InMed Pharmaceuticals Inc (INM) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
